ImmPACT Bio is a technology company.
ImmPACT Bio has raised $140.0M across 1 funding round.
ImmPACT Bio has raised $140.0M in total across 1 funding round.
ImmPACT Bio has raised $140.0M in total across 1 funding round.
ImmPACT Bio's investors include 5AM Ventures, Apollo Health Ventures, Foresite Capital, MPM Capital, OrbiMed, RA Capital, venBio, Venrock.
ImmPACT Bio is a clinical-stage biotechnology company developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies to treat cancer and autoimmune diseases, targeting cancerous or autoreactive cells while sparing healthy tissues.[1][2][3] Its lead product, IMPT-314, is a bispecific CD19/CD20 CAR T therapy in Phase I/II trials for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, with IMPT-514 advancing for multiple sclerosis after FDA IND clearance in 2025.[4][5] The company serves patients with exhausted treatment options in oncology and autoimmunity, addressing challenges like antigen escape, on-target/off-tumor toxicities, and immunosuppressive tumor microenvironments, and raised $165.86M before its October 2024 acquisition by Lyell Immunopharma.[1][5]
ImmPACT Bio was founded in 2017 within the FutuRx incubator in Israel, leveraging technologies from pioneering scientists including Prof. Gideon Gross (MIGAL – Galilee Research Institute), Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA.[2][3] In 2019, it established U.S. headquarters in West Hills, California (later Camarillo for R&D), with additional operations in Rehovot, Israel; by 2021, it merged with Kalthera to expand its pipeline.[1][3] Early traction came from licensing UCLA's logic-gate CAR T platforms, filing 7 patents (e.g., inhibitory CARs granted in 2023), and advancing to clinical stages amid CAR T's rise in hematological malignancies.[1][2]
ImmPACT Bio rides the CAR T expansion from blood cancers to solid tumors and autoimmune diseases like MS, where current therapies face antigen escape and toxicity hurdles.[3][4][5] Timing aligns with FDA nods (e.g., IMPT-514 IND in 2025) and manufacturing optimizations amid scalability demands, fueled by market forces like rising lymphoma/MS prevalence and investor interest in next-gen cell therapies.[2][4] Its acquisition by Lyell in October 2024 consolidates expertise, enabling Lyell to pivot fully to CAR T (dropping TIL programs) and launch pivotal IMPT-314 trials in 2025, influencing ecosystem shifts toward bispecific, logic-gated approaches for broader adoption.[1][5]
Post-acquisition, ImmPACT's therapies integrate into Lyell's pipeline, with IMPT-314 Phase I/II data expected soon and pivotal third-line lymphoma trials starting 2025, plus IMPT-514 dosing in MS trials mid-2025.[4][5] Trends like automated manufacturing and autoimmune CAR T applications will shape progress, potentially evolving its influence via Lyell's resources into transformative, one-time treatments resetting immune dysfunction in hard-to-treat diseases. This positions the logic-gate platform as a cornerstone for CAR T's next era, building on its targeted precision to expand beyond oncology.
ImmPACT Bio has raised $140.0M across 1 funding round. Most recently, it raised $140.0M Series B in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $140.0M Series B | 5AM Ventures, Apollo Health Ventures, Foresite Capital, MPM Capital, OrbiMed, RA Capital, venBio, Venrock |